Featured Clinical Trial:

Multiple myeloma, newly diagnosed (product/compound: lenalidomide; dexamethasone; elotuzumab)

ClinicAid Locations: Southern California – Fountain Valley, Corona, Riverside

Status:
Open for enrollment (accepting patients). Please contact us and mention Trial ID NCT01335399.

Condition: Multiple Myeloma

Product Name/Compound: Lenalidomide; Dexamethasone; Biological: Elotuzumab

Full Study Title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma

Study Summary: The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS)

Eligible Participants:

Inclusion (Eligible):

• Men and women >= 18 years of age
• Subjects who are newly diagnosed with symptomatic Multiple Myeloma (MM) and who:
  • have not received any prior systemic anti-myeloma therapy AND
  • have measurable disease AND
  • are not candidates for high-dose therapy plus stem-cell transplantation because of age (>= 65 years) or coexisting conditions

Exclusion (Not Eligible):

• Subjects with non-secretory or oligo-secretory or free light-chain only myeloma
• Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions
• Monoclonal Gammopathy of Undetermined Significance (MGUS)
• Active plasma cell leukemia
• Positive for Hepatitis B, C or Human Immunodeficiency Virus (HIV)

Study Phase: Phase III (What are Phases?)

To receive information and updates for this trial:
Please contact us and mention the Trial ID below.

Trial ID (ClinicalTrials.gov): NCT01335399

<< Back to all ClinicAid clinical trials